Pfizer-J&J Drop Alzheimer’s Drug Studies After Failure

Pfizer Inc., Johnson & Johnson and Elan Corp. ended most plans to develop an Alzheimer’s drug after a second trial failure, a blow to the companies’ efforts to market the first product to slow progress of the disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.